title: Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab.
abstract: BACKGROUND
  We wanted to determine whether multiple injections of intravitreal ranibizumab was associated with an elevated intraocular pressure (IOP) in patients treated for neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  This retrospective study examined 53 patients with neovascular AMD treated with multiple injections of intravitreal ranibizumab. The main outcome measure was the difference in IOP between the frequently-treated study eyes (≥15 injections) and the unfrequently-treated fellow control eyes (≤ five injections). Patients were divided into three study groups: group I (35 patients with 15 to 19 injections); group II (15 patients with 20 to 29 injections); and group III (three patients with ≥30 injections). The IOP was measured by Goldmann applanation tonometry 4 weeks after the last injection of intravitreal ranibizumab. For statistical analysis, the IOP was then correlated with the number of ranibizumab injections.
  
  
  RESULTS
  Among the frequently-treated study eyes, the mean IOP was 13.68±2.91 mmHg (range, 8 to 20 mmHg). The unfrequently-treated fellow control eyes had a mean IOP of 13.45±3.09 mmHg (range, 9 to 25 mmHg). There was no significant correlation of the IOP difference between the study and control eyes with the number of ranibizumab injections (correlation coefficient 0.77; P=0.583). For each of groups I, II, and III, the difference in mean IOP between the study and control eyes was nonsignificant (P>0.05). There was also no significant association of the IOP difference between the study and control eyes with the number of ranibizumab injections for each group (P=0.391).
  
  
  CONCLUSIONS
  Our study did not find an increased IOP in frequently-ranibizumab-treated eyes when compared to unfrequently-treated fellow control eyes. Further studies with a greater sample size are needed to evaluate whether an increased number of ranibizumab injections is associated with IOP changes.
authors.affiliation: Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: Alice L
authors.initials: AL
authors.lastname: Yu
authors.affiliation: Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: Florian
authors.initials: F
authors.lastname: Seidensticker
authors.affiliation: Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Schaumberger
authors.affiliation: Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Welge-Lussen
authors.affiliation: Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: Armin
authors.initials: A
authors.lastname: Wolf
keywords: age-related macular degeneration; anti-VEGF therapy; ocular hypertension
references.citation: Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):955-8
references.pmid: 18425523
references.citation: Retina. 2008 Jul-Aug;28(7):996-1001
references.pmid: 18698303
references.citation: Ophthalmic Surg Lasers Imaging. 2012 Jul 1;43(4):328-34
references.pmid: 22788585
references.citation: Retina. 2011 Jun;31(6):1028-35
references.pmid: 21836409
references.citation: Ophthalmology. 2009 Nov;116(11):2264.e1-3
references.pmid: 19883862
references.citation: J Glaucoma. 2012 Apr-May;21(4):241-7
references.pmid: 21423038
references.citation: Expert Opin Pharmacother. 2012 Aug;13(12):1679-94
references.pmid: 22783878
references.citation: Eye (Lond). 2009 Jan;23(1):181-5
references.pmid: 17693999
references.citation: Retina. 2007 Oct;27(8):1044-7
references.pmid: 18040242
references.citation: N Engl J Med. 2006 Oct 5;355(14):1432-44
references.pmid: 17021319
references.citation: Retina. 2006 May-Jun;26(5):495-511
references.pmid: 16770255
references.citation: Br J Ophthalmol. 2006 Nov;90(11):1344-9
references.pmid: 16854824
references.citation: Br J Ophthalmol. 2011 Aug;95(8):1111-4
references.pmid: 20702430
references.citation: N Engl J Med. 2006 Oct 5;355(14):1419-31
references.pmid: 17021318
references.citation: Clin Ophthalmol. 2011;5:1303-8
references.pmid: 21966206
references.citation: Ophthalmology. 2012 Feb;119(2):321-6
references.pmid: 22054994
references.citation: Am J Ophthalmol. 2008 Dec;146(6):930-4.e1
references.pmid: 18775528
references.citation: Br J Ophthalmol. 2008 Apr;92(4):584
references.pmid: 18369083
references.citation: Drugs Aging. 2012 Dec;29(12):949-56
references.pmid: 23179897
references.citation: Br J Ophthalmol. 2010 Jan;94(1):2-13
references.pmid: 19443462
references.citation: J Ocul Pharmacol Ther. 2010 Feb;26(1):105-10
references.pmid: 20187807
references.citation: Ophthalmologica. 2013;229(3):168-72
references.pmid: 23548723
references.citation: Retina. 2012 Jul;32(7):1295-301
references.pmid: 22466465
references.citation: Curr Opin Ophthalmol. 2012 Mar;23(2):105-10
references.pmid: 22249237
references.citation: Can J Ophthalmol. 2007 Dec;42(6):807-11
references.pmid: 18026202
references.citation: Acta Ophthalmol. 2013 Sep;91(6):526-30
references.pmid: 22697404
references.citation: Retina. 2010 Jun;30(6):887-92
references.pmid: 20458261
references.citation: Ophthalmologica. 2012;227(3):132-8
references.pmid: 22212151
references.citation: Open Ophthalmol J. 2010 Jun 22;4:28-9
references.pmid: 20871754